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The skin is permanently exposed to physical, chemical, and biological aggression by the environment. In addition, acute and
chronic inﬂammatory events taking place in the skin are accompanied by abnormal release of pro-oxidative mediators. In this
paper, we will brieﬂy overview the homeostatic systems active in the skin to maintain the redox balance and also to counteract
abnormal oxidative stress. We will concentrate on the evidence that a local and/or systemic redox dysregulation accompanies the
chronic inﬂammatory disorder events associated to psoriasis, contact dermatitis, and atopic dermatitis. We will also discuss the
fact that several well-established treatments for the therapy of chronic inﬂammatory skin disorders are based on the application
of strong physical or chemical oxidants onto the skin, indicating that, in selected conditions, a further increase of the oxidative
imbalance may lead to a beneﬁcial outcome.
1.Introduction
Epithelial cells are the outermost viable components of the
skin and mucous membranes, and are the fundamental
generators of highly specialized physicochemical barriers,
that is, organized tissues that exist primarily to deﬁne and
separate distinct compartments of the body with the aim
to protect the host in its entirety and preserve single organ
functions homeostatically. These protective functions are
obviously maximal in the skin, the conjunctiva and the
respiratory mucosa, since they deﬁne boundaries with direct
contact with the environment. Normally, environmental
microorganisms, toxins, and allergens are eﬃciently blocked
from entry by the defence wall organized by layers of
epithelial cells. In the viable portion of the epidermis, lipid
plasma membranes, and highly speciﬁc membrane transport
systemsposeaformidableobstacletotransepithelialpassages
of most undesired molecules. In addition, intercellular
junctional barrier connections (or tight junctions) create
a continuum with the epithelial cell cytoskeleton, and are
conserved even when epithelial cells divide or apoptose [1].
However, much of the physicochemical barrier function of
humanepidermisagainsttheenvironmentisprovidedbythe
corniﬁed cell envelope (CE), a unique, highly lipophilic two-
compartment system of corneocytes embedded in a lipid-
enriched intercellular matrix [2]. Moving upward from the
deepest layers of the epidermis, keratinocytes progressively
diﬀerentiate and eventually become anucleated corneocytes,
formed of cross-linked keratins enclosed within an insoluble
matrix of proteins and surrounded by a ceramide-rich lipid
envelope. Both protein and lipid components of CE are
essential for an optimal barrier function, as demonstrated
by genetic defects underlying several human diseases and a
number of mouse models [3, 4].
2. Mechanismsof Redox Balance inthe Skin
In the healthy skin, practically all types of skin cells
produce reactive oxygen (ROS) and reactive nitrogen (RNS)
species[5].Forexample,bothmelanocytesandkeratinocytes
p r o d u c eh y d r o g e np e r o x i d e( H 2O2) and superoxide radicals
in the reaction of pheomelanin with UV light [6]. All cells
also produce small amounts of superoxide anion as by-
product of electron transfer in the mitochondrial respiratory
chain. By reacting with lipid molecules directly, or aﬀecting2 Mediators of Inﬂammation
redox-sensitivelipid-metabolizingenzymes(phospholipases,
lipoxygenases, and cyclooxygenases), ROS induce produc-
tion of reactive lipid species (lipid radicals, peroxides,
hydroperoxides, aldehydes, etc.). Although dismutation of
superoxide anion probably accounts for much of the H2O2
produced by eukaryotic cells, it can also be formed by direct
two-electron reduction of oxygen, a mechanism shared by
a number of ﬂavoprotein oxidases [7]. Importantly, nitric
oxide (NO) and peroxynitrite are major RNS in biological
systems. In the skin, NO is produced by two constitutive
nitricoxidesynthase(cNOS)isoforms,identiﬁedasendothe-
lial(eNOS)andneuronal(nNOS),andoneinducible(iNOS)
isoform. Both ﬁbroblasts and keratinocytes constitutively
express eNOS. NO easily reacts with oxidative species,
including ROS, transition metals and thiols to yield various
RNS. In particular, NO reacts with superoxide anion at
near diﬀusion-limited rates, leading to the extremely rapid
production of the peroxynitrite ion. When generated at
high concentrations, peroxynitrite can diﬀuse and undergo
transformation into other powerful oxidants, including the
hydroxyl radical (OH·) and other RNS (NO2,N O 2
+)[ 8]. It
is important to emphasize that low levels of highly reactive
ROS and RNS are indispensable eﬀectors in the homeo-
static pathways leading to cell proliferation, diﬀerentiation,
senescence, and death, and a vast body of evidence conﬁrms
that this is true also for the distinct cell populations of the
human skin, as extensively commented elsewhere [5]. Due
to its direct contact with environmental physicochemical
challenges, the skin is peculiarly rich of eﬀective antioxidant
systems(Figure 1).Intheviablelayersoftheepidermis,lipid-
soluble antioxidants, mainly alphatocopherol, and antiox-
idant enzymes like catalase (CAT), superoxide dismutases
(SOD), glutathione peroxidases (GPx), and peroxiredoxins
are abundantly expressed [9] .T h ee x t r a c e l l u l a rs p a c eo fs k i n
epidermis and dermis, contains large amounts of water-
soluble antioxidants such as ascorbic acid, uric acid, and
glutathione. In addition to eﬀectively counteract insults
comingfromtheenvironment,theCEofnormalhumanskin
contains high levels of water and lipid-soluble antioxidants
such as glutathione, thioredoxin, vitamin C, uric acid, α-
tocopherol, squalene, and coenzyme Q10, distributed in
a gradient with the highest concentration on the deepest
CE layers [10]. As part of an adaptive response, abnormal
levels of ROS also induce the expression of ROS-detoxifying
enzymes. In order to protect the structural and functional
integrity of the skin, a wide spectrum of phase I enzymes,
active both in oxidation and reduction, and phase II
enzymes, active in conjugation reactions, can be found
upregulatedintheskin,orcanberapidlyinducedinresponse
to diﬀerentphysicalandchemicalagents.Thetranscriptional
response to these agents is typically mediated by the cis-
acting antioxidant response element (ARE), found in the
promoter of the encoding genes for diverse products such
as several glutathione S-transferases, metalloproteinases,
NADPH:quinone oxidoreductase 1, UDP glucuronotrans-
ferase, γ-glutamate cysteine ligase, heme oxygenase 1, and
peroxiredoxin VI. The major ARE-binding transcription
factor is nuclear factor-erythroid 2-related factor 2 (Nrf2),
which, through heteromeric interaction with the small
Maf proteins, binds the ARE and initiates the de novo
expression of detoxifying enzymes [11].Intheskin, although
several Nrf2-dependent ROS-detoxifying enzymes are found
upregulatedinwoundhealing,abrogationofNrf2expression
in transgenic mice is substantially irrelevant for the healing
process, whereas it is essential for the eﬀective detoxiﬁcation
of chemical carcinogens [12]. These observations emphasize
the special chemopreventive role of Nrf2-controlled genes in
the skin. The transcriptional activation of Nrf2-dependent
genes can be induced by various chemicals, including
redox-active compounds such as quinones, isothiocyanates,
peroxides,mercaptans,transitionmetals,trivalentarsenicals,
and also by chemopreventive antioxidants such as dietary
polyphenols [11].Bycontrast,chemopreventive polyphenols
may oppose inﬂammation and cancer by enhancing cellular
antioxidant and detoxifying enzymes via activation of Nrf2.
They also suppress the induction of proinﬂammatory and
growth-promoting genes by downregulating the activation
ofthecrucialtranscriptionfactorsNuclearFactorκB(NFκB)
and activator protein 1 (AP-1) [13]. In response to a variety
of oxidant reactants, the skin upregulates transactivating
AP-1 components such as Fos and Jun, whereas it down-
regulates its negative, anti-inﬂammatory components Fra-
1 and Fra-2. The shift of redox balance towards oxidative
conditions facilitates phosphorylation and activation of c-
Jun N-terminal kinase (JNK), a kinase that promotes Jun
translocation into the nucleus. As a result, transcription
of AP-1-dependent genes takes place and, if this process
persists, cells will eventually die by apoptosis. Ascorbic
acid is an antiapoptotic antioxidant, which provides redox-
dependentinhibitionofJNKandactivationofFra-1andFra-
2. A detailed analysis of the redox modulation of the signal
transduction pathways and transcription factors involved in
the inﬂammatory response of the skin has been recently
published [14].
3.Redox ImbalanceinTCell-Mediated
Skin Inﬂammation
T cell-mediated diseases of the skin are chronic disorders
with a high-social impact and an increasing prevalence
in the western countries. These diseases include psoriasis,
contact dermatitis, and atopic dermatitis. In the last decades,
relevant advances have been achieved in the understanding
of the cellular and molecular mechanisms underlying these
disorders [15]. Similar to the inﬂammatory events taking
place in other organs, also chronic skin inﬂammation
associates with overproduction of ROS, RNS, and high levels
of products of lipid peroxidation. Here, we will brieﬂy review
recent acquisitions on the pathogenesis of T cell-mediated
skin disorders, and the evidence of disease-speciﬁc redox
imbalance.
3.1. Pathogenesis of Psoriasis. P s o r i a s i si sc h a r a c t e r i z e db ya n
intrinsicallydysregulatedinterrelationbetweenkeratinocytes
and cells of both the innate and acquired immune response
[16].Asaresult,psoriatickeratinocytesaberrantlyproliferateMediators of Inﬂammation 3
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Figure 1: Sources and responses to reactive oxygen and nitrogen species (ROS and RNS) in the skin. These highly reactive entities are
generated as a result of normal intracellular metabolism in mitochondria and peroxisomes, and by a variety of cytosolic enzyme systems.
The skin is peculiarly rich of enzymatic and nonenzymatic systems for the regulation of overall ROS and RNS levels and hence for the
maintenance of physiological homeostasis, due to its direct contact with strong pro-oxidative physical and chemical insults from the
environment. These include UV and ionizing radiations, and a variety of pollutants. During chronic inﬂammatory events, the persistent
release of potent cytokines by inﬁltrating leukocytes contribute to perturb the redox balance, essentially through the upregulated expression
of numerous enzymes involved in the regulation of this balance. Lower-than-normal levels of ROS and RNS leads to impaired cell
proliferation and reduced host defence. Also an increase in their levels is detrimental for the skin, leading to damage to cell components
and eventually acceleration of ageing and age-related diseases.
and become a reservoir of inﬂammatory mediators that,
directly and indirectly, induce the psoriatic phenotype. In
the last years, a number of studies have highlighted the
central involvement of dermal dendritic cells (DCs) in the
pathogenesis of psoriasis. In particular, dermal myeloid
DCs are increased in psoriatic lesions and induce T cell
proliferation and the massive production of the type 1
cytokine interferon (IFN)- γ [17]. A specialized subgroup
of these cells is named tumor necrosis factor (TNF)-α and
iNOS-producing DC (TIP-DC), due to their high expression
of these inﬂammation markers [18]. The evidence that
targeted immunotherapy reduces the quantity of these cells
in psoriatic patients supports the concept that these cells
are associated to the disease and have a pathogenetic role
[18, 19]. Importantly, TIP-DC can also produce IL-20 and
IL-23, and stimulate the diﬀerentiation and activation of
IL-17-producing helper T cells (Th17) [20]. Th17 cell type
is specialized in the immunosurveillance of the epithelium,
and also secretes high levels of IL-22, a key cytokine linking
adaptive immune eﬀectors and epithelial dysregulation in
psoriasis. Indeed, IL-22, rather than IL-17A, from which
Th17 cells are named, is emerging as the prototypic Th17
cytokine [21], by inducing proliferation of keratinocytes
and synergizing with IL-17 in the enhanced expression of
antimicrobialpeptidesandchemokinesbyskinkeratinocytes
[21, 22]. Hence, IL-22 could be centrally involved in the
pathogenesisofpsoriasis,adiseasecharacterizedbyveryhigh
levels of numerous chemokines and antimicrobial peptides
[16]. A ﬁrst functional role of Th17 cells in psoriasis was
suggested by reduction of their number during successful
anti-TNF treatment [23, 24]. In addition, a population of
plasmacytoid DC (pDC) is now thought to be crucially
implicated in the early phases of the psoriatic plaque
formation. These cells release IFN-α in the skin, and this
event is currently believed to trigger the expansion of
autoimmune T cells. In humans, inﬁltration of pDC and
expression of IFN-α can be detected early and transiently
during the development of the psoriatic plaque whereas
its eﬀect persists in time until lesion chronicization [25].
In contrast, pDC are almost absent in chronic psoriatic
lesions.Alsotheexpressionofchemerin,achemotacticfactor
active speciﬁcally on pDC recruitment through its binding
to the Chemerin R23 receptor on their surface [26], can be
observed only in association with early pDC inﬁltration in
psoriatic skin [25].
3.2. Evidence of Oxidative Stress in Psoriasis. There are many
systemic and lesion-restricted signs of severe oxidative stress
in the patients with active psoriasis [27]. In the plasma and
red blood cells of patients with active psoriasis, increased
levels of malonyl dialdehyde (MDA) were interpreted as
the ﬁngerprint of the exhaustion of natural enzymatic
and nonenzymatic antioxidant defenses and consequently4 Mediators of Inﬂammation
the prevalence of deleterious peroxidative processes in the
cell membranes and plasma lipids of circulating cells [28,
29]. In another study, erythrocytes from psoriatic patients
presented a statistically signiﬁcant decrease in erythrocyte
SOD and GPx [30]. In this report, exaggerated levels of
MDA were measured in the lesional tissues but not in
the serum of psoriatic patients. Other authors described a
decreased antioxidant potential of the plasma, along with
higher-than-normal expression of SOD, and elevated MDA
levels but no correlation between these parameters and the
disease severity [31]. Taken together, these results support
the notion that an imbalance in the oxidant-antioxidant
system can be observed in psoriatic patients [32]. In the
skin lesion, the massive inﬁltration of the various leukocyte
populations in an activated state certainly leads to local
release of a number of pro-oxidative species, in their
turn implicated in the proinﬂammatory activation of the
resident cells of the skin, in particular, keratinocytes and
ﬁbroblasts [14].
Interestingly, several proinﬂammatory mediators re-
markably upregulated in the psoriatic lesions, in particular
TNF-α,I F N - γ, and IL-8, are strong inducers of iNOS expres-
sion and NO release from the epidermal keratinocytes [33,
34]. In addition, psoriatic lesions are peculiarly inﬁltrated
by TIP-DC, characterized by abundant levels of iNOS, as
previously described in [18, 19]. Being a potent regulator
of keratinocyte growth and diﬀerentiation, NO has been
recently considered a key player in the pathogenesis of
psoriasis. Indeed, a large body of work suggests that NO
is proinﬂammatory in the skin. Application of an NO-
releasing cream on the skin of healthy subjects elicits an
inﬂammatory response, and a loss of Langerhans cells that
wascorrelatedtoupregulatediNOSactivityduringtheUVB-
induced erythematous response [35, 36]. However, other
investigators found that application of an NO-releasing oint-
ment on active psoriatic lesions leads to disease regression,
possibly due to prominent NO-dependent downregulation
of chemokine expression and hence to inhibition of T cell
andmacrophageattractionintotheskin[37].Thislastreport
emphasizes a possible beneﬁcial eﬀect of NO on this chronic
disorder, and suggests that the actual levels of NO are lower
than normal in psoriatic lesions. Accordingly, the evidence
thatarginase1isaberrantlyoverexpressedinthelesionalskin
of psoriasis patients suggests the possibility that arginine,
which is the substrate for NO generation by iNOS, might
not be adequately available for iNOS activity [38]. Also an
abnormalgenerationofthesuperoxideanioncouldlimitNO
concentration in the psoriatic lesion, since this species may
rapidly react with NO and generate peroxynitrite, a cytotoxic
agent that nitrosylates thiolic groups and also leads to DNA
break [39]. Of relevance, exogenous NO was shown to
exhibit a biphasic action on HaCaT keratinocytes, providing
a proliferative signal at lower concentrations (below 100
micromolar), and inducing cell cycle arrest at higher doses
[40].
In spite of the evidence that an oxidative stress is sys-
temically and locally present during this disease, a variety of
eﬀective treatments currently used for the therapy of psoria-
sis rely on a boost of the oxidative stress itself. For example,
psoralen-UVA (PUVA) combined therapy is widely used in
the treatment of psoriasis, and it leads to massive generation
of singlet oxygen in the skin [41]. Solar irradiation is also
known to improve the clinical conditions in a considerable
proportion of patients with psoriasis [16]. In the whole
human skin in vivo, the sun light induces production of
IL-6 accompanied by increased levels of 8-isoprostane, a
marker of oxidative damage to skin lipids [42]. Also broad-
band UVB phototherapy was successfully introduced into
therapeutic protocols for psoriasis. UVB phototherapy leads
to a sharp increase in the levels of thiobarbituric acid (TBA)
products and nitrite/nitrate concentration in the plasma of
patients subjected to a 1 to 2-month-long treatments [43].
In patients aﬀected by severe forms of psoriasis, systemic
treatments include methotrexate, an inducer of elevated
nitrite/nitrate levels in the serum [44]. Fumaric acid esters
are also used for the systemic therapy of psoriasis with good
clinical eﬃcacy. Elevation of superoxide anion production
by circulating blood monocytes in patients treated with
this drug was documented [45]. Finally, anthralin is a
well-established topical treatment for psoriasis. Its positive
clinical eﬀect seems to associate to hydrogen peroxide-
induced activation of EGF receptor in keratinocytes [46].
Pro- and antioxidant properties of anthralin and some of
its derivatives have been characterized [47]. In their whole,
these observations suggest that a further increase of the
local levels of oxidative imbalance can play a beneﬁcial, anti-
inﬂammatory eﬀect in the skin of psoriatic patients, possibly
due to activation of antiproliferative, proapoptotic pathways
in both resident and inﬁltrating cell populations.
3.3. Pathogenesis of Allergic Contact Dermatitis. Allergic con-
tact dermatitis (ACD) is a common inﬂammatory skin dis-
ease,inducedbyrepeatedcontactwithlowmolecularweight,
highly reactive chemicals called haptens [48]. This disease
aﬀectsabout5%ofmenand11%ofwomeninindustrialized
countries and has a chronic evolution. While the irritant
contact dermatitis (ICD) is a nonspeciﬁc inﬂammatory
dermatosis mainly due to severe damage to the epidermal
barrier and/or direct toxicity of the xenobiotics or chemicals
on the skin cells, ACD is a delayed-type hypersensitivity
response, with skin damage eventually due to activation of
theacquiredimmunityandinﬁltrationofthetissuesbyarich
population of lymphocytes including hapten-speciﬁc T cells.
Indeed, haptens irreversibly change the chemical nature of
endogenous proteins, and hence trigger an antigen-speciﬁc
response in the course of a second re-exposure. The cellular
mechanism behind this adaptive response has been deeply
investigated in the last decades [15]. Hapten interaction
with extracellular or membrane-bound proteins is followed
by internalization into skin antigen presenting cells, mostly
Langerhans cells and dermal DCs, and processed into major
histocompatibility complex (MHC) class II compartments
to generate appropriate hapten-peptide complexes ﬁtting in
the groove of MHC molecules. Skin DCs reside in the skin
in an immature state, characterized by their high capacity
to capture antigens penetrated through the CE, but very
low-antigen presenting capacity [49, 50]. Both LangerhansMediators of Inﬂammation 5
cells and dermal DCs are susceptible to environmental
stimuli such as irritants, toxic stimuli, and bacterial and viral
products, which promote their migration to regional lymph
nodes and the acquisition of antigen presenting capacity for
na¨ ıve T-cell priming and diﬀerentiation. Cytokines released
by skin resident cells, in particular IL-1, TNF-α,a n dI L -
18, critically regulate both DC migration and functional
maturation[51].Oncemigratedintotheparacorticalzoneof
draining lymph nodes, skin DCs prime hapten-speciﬁc na¨ ıve
Tl y m p h o c y t e s ,w h i c hd i ﬀerentiate into memory/eﬀector T
cells and acquire deﬁned migratory behavior towards the
skin, so that they will speciﬁcally migrate into the skin upon
a further contact with the same hapten. Similar to what can
be found in the psoriatic lesion, high levels of TNF-α and
IFN-γ are released by activated leukocytes also in ACD, and
contribute to stimulate a strong proinﬂammatory program
in the resident cells of the skin.
3.4. Evidence of Oxidative Stress in ACD. Oxidative stress is
regarded as widely implicated in the molecular mechanisms
leading to both ICD and ACD [52]. Examples of irritants
or antigens with overt oxidizing behavior are numerous,
and include hydroperoxides and peroxides, metal salts such
as nickel (II) or chromium (VI), quinines, and primary
amines [53]. All these substances may determine oxidative
stress in the cell and dysregulate its molecular mechanisms,
or may themselves require redox metabolism to become
antigenic. The proinﬂammatory activity of ROS-generating
chemicals in the skin is exempliﬁed by the induction of
ICD through intradermal injection of hydrogen peroxide-
producing enzymes including glucose oxidase, a reaction
that can be neutralized by simultaneous administration
of CAT or SOD [54]. Systemic or topical treatment with
N-acetylcysteine prior to epicutaneous application of the
strong sensitizer and frankly oxidant compound 2,4,6-
trinitro-1-chlorobenzene, reduces all the inﬂammation-
correlatedparameters,includingexpressionofproinﬂamma-
tory cytokines, edema, and extent of leukocyte inﬁltration
[55]. The group of strong sensitizers with a dinitrohaloben-
zene structure, namely, 2,4-dinitro-1-ﬂuorobenze and 2,4-
dinitro-1-chlorobenzene, were shown to irreversibly inhibit
mammalian thioredoxin reductase [56], hence eliminating
thioredoxin contribution to the maintenance of intracellular
r e d o xb a l a n c e .I nt h ep o s i t i v ep a t c ht e s tf o rA C Dt o
nickel (II), an abnormal elevation of the oxidized/reduced
glutathione ratio and an increase in the levels of iron can
be detected in the skin lesion [57]. In contrast, induction of
ACDtopolyaromatichydrocarbonsrequiresthebiosynthesis
of a reactive oxidative intermediate by cytochrome P450-
dependent enzymes [58]. Also paraphenylenediamine, a very
diﬀuse agent of ACD in the industrialized world, requires a
cytochromeP450-dependentenzymetobecomereactiveand
elicit the disease [59]. Finally, the depletion of the enzymatic
and/or nonenzymatic antioxidant defenses precipitates the
cells in a condition of oxidative stress, which represents
a robust trigger for the activation of a proinﬂammatory
response. In particular, activation of the redox-sensitive
NFκB pathway leads to the de novo expression of a plethora
of cytokines and chemokines by resident cells [53, 60]
and eventually to tissue damage, due to massive leukocyte
inﬁltration.
An increase of iNOS was found immunohistochemically
both in ICD and ACD [61], and hence NO can reasonably
play a role in the distinct processes going on in contact
with dermatitis, including enhanced proliferation of epider-
mal cells, neutrophil accumulation and local vasodilatation
[62]. Indeed, iNOS blockade by aminoguanidine prior to
immune challenge was shown to reduce the inﬂammatory
response to the sensitizers picryl chloride and 2,4-dinitro-
1-ﬂuorobenze [63, 64]. In humans, topical application of
an NO-releasing cream provides a suﬃcient stimulus to
induce ICD, as previously discussed in [36], although an
independent investigation suggests that NO exerts a more
complex regulation of the inﬂammatory skin reactions, with
potentiation of immune-speciﬁc cell-mediated mechanisms,
but limited role during ICD [65].
3.5. Pathogenesis of Atopic Dermatitis. Atopic dermatitis
(AD) is a chronic inﬂammatory disease that results from
complex interactions between genetic and environmental
factors [66]. A defect of total lipids of the CE, including
sterol esters and phospholipids as well as an increase in
free fatty acids and sterols compared to normal controls,
is responsible of the xerotic aspect of the atopic skin, and
may determine a higher permeability to allergens and irri-
tants, including environmental toxins. Recent ﬁndings have
provided evidence that a disturbed protease-antiprotease
balance is also implicated in a faulty diﬀerentiation process
of keratinocytes and accelerated desquamation in this dis-
ease [66]. However, the strongest evidence for a primary
structural abnormality of CE underlying the pathogenesis
of AD derives from the recent link between loss-of-function
mutations in the gene encoding ﬁlaggrin and AD [67, 68].
Up to 50% of European children with AD reveal single
or double allele, or compound mutations in the ﬁlaggrin
gene on chromosome 1q21. Although 15 distinct mutations
have been reported, the 2 most common account for
the majority of cases [69], and because of their proximal
location on the ﬁlaggrin gene, they also predict more severe
loss of function. Filaggrin deﬁciency in the epidermis of
AD patients is reasonably implicated in diﬀerent, not yet
clearly deﬁned, aspects of CE malfunction in these subjects,
including poor CE hydration and decreased generation of
ﬁlaggrin acidic metabolites such as transurocanic acid, with
consequent uncontrolled activation of serine proteases [70].
Any perturbation of the epidermal permeability barrier
representsperseaneﬀectivemechanismleadingtocutaneous
inﬂammation, since numerous cytokines, chemokines, and
some of the growth factors released by keratinocytes as
autocrine regulators of barrier homeostasis can also favor
the development of inﬂammatory reactions [71]. Of note,
keratinocytes of AD patients exhibit propensity to an exag-
gerated production of distinct cytokines and chemokines;
a phenomenon that can be relevant in further promoting
and maintaining local inﬂammation [66]. As a consequence,6 Mediators of Inﬂammation
speciﬁcimmuneresponsesagainstavarietyofenvironmental
allergens are often present, with a bias towards T helper
2 (Th2) immune responses. Atopic diseases are indeed
characterized by IgE hyperresponsiveness to environmental
allergens and a peculiar hyperreactivity of the target tissues
toward irritative/inﬂammatory stimuli.
3.6. Evidence of Oxidative Stress in AD. Factors predisposing
susceptible individuals to atopic diseases include chronic
exposure to oxidative toxins, such as tobacco smoke and
air pollution [72]. Also the relevance of the psychological
stress as a risk factor for the precipitation of the atopic
syndrome is widely accepted, although the mechanisms of
this immunoregulation are poorly understood [72]. Impor-
tantly, there is intriguing experimental evidence that chronic
psychological stress augments oxidative tissue damage, as
demonstrated by the increase of 8-hydroxy-deoxyguanosine
(8-OH-dG), a parameter of oxidative DNA damage, in the
plasma of animals undergoing permanent painful stim-
uli [73]. In children with acute exacerbation of atopic
dermatitis, urine concentrations of 8-OH-dG, of acrolein-
lysine adducts (markers of lipid peroxidation), and of biliru-
bin oxidative metabolites (markers of bilirubin oxidative
metabolism) were higher than those of control subjects,
and returned to normal levels during disease remission.
In contrast, nitrite/nitrate levels (markers of endogenous
nitric oxide production) were not signiﬁcantly aﬀected
in these patients [74]. Upregulation of urinary 8-OH-dG
was reported in adult patients undergoing exacerbation of
the disease [75]. These ﬁndings suggest that AD patients
experience an oxidative stress, and that altered antioxidant
defences are possibly involved in the pathophysiology of the
acute form [28, 32]. Evidence of enhanced protein and lipid-
oxidative damage was found in the CE of atopic patients,
as demonstrated by the increase of carbonyl moieties both
in lesional and nonlesional skin, along with an elevation in
the activity of SOD, an eﬀective scavenger of ROS, possibly
as part of a mechanism that tends to buﬀer the persistence
of oxidative stress [76]. Recent animal data support a role
for oxidative/antioxidative imbalance in the shift toward a
Th2-skewed immune response [77]. Accordingly, a previous
report demonstrated that administration of the antioxidant
thiol N-acetyl-L-cysteine or glutathione to human T cells in
culturedownregulatedtheTh2polarization,withdecreasein
the expression of IL-4 and IL-5 and simultaneous skewing
towards a Th1-type phenotype [78]. These observations
indicate that antioxidant supplementation could represent
a good therapeutic approach for the treatment of AD. Also
the topical use of a proper antioxidant onto the lesional skin
could reasonably help to dampen the aberrant keratinocyte
expression of cytokines and chemokines in response to
proinﬂammatorystimuli[79].However,thepotentialbeneﬁt
of topical antioxidant treatments in preventing relapses of
the disease or in accelerating its remission, has not been
clinicallyassessed.Bycontrast,similartopsoriasis,severeAD
canbeneﬁtofexposuretoUVlightandtreatmentwithPUVA
[80], due to a system of responses that lead to eﬀective local
immunosuppression.
4. Conclusions
In this paper, we have brieﬂy overviewed our current knowl-
edge of the systemic and local redox imbalance in chronic
skin inﬂammation. The experimental evidence collected so
far suggests that the pattern of redox perturbation is disease-
speciﬁc, and that several well-established, eﬀective pharma-
cological treatments display a frank pro-oxidant behaviour.
In particular, a number of drugs and physical approaches
used in the therapy of psoriasis behave as strong sys-
temic and/or local oxidants. In this case, oxidation-induced
damage to the cell cycle machinery of hyperproliferating
keratinocytes, and of massive numbers of inﬁltrating leuko-
cytes might eventually perform a valid immunosuppression
that helps reduction and/or remission of the plaques. Of
note, UV-based therapy is also eﬀective in the therapy of
severe AD. Nonetheless, the anti-inﬂammatory behaviour
of numerous natural polyphenols on a variety of cell
populations including skin cells, could be ideally employed
toprotecttheskinfromabnormalresponsetoenvironmental
triggers and prolong the disease-free periods [81]. To reach
this goal, a further step forward in the investigation of
the complex, molecule-speciﬁc mechanisms of action of
natural antioxidant compounds is necessary, along with
double-blind placebo-controlled clinical trials to establish
parameters of eﬃcacy and safety of these compounds.
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